Back to News
Market Impact: 0.35
AbbVie Completes Acquisition of Apogee Therapeutics
Source: PR Newswire
M&A & RestructuringHealthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
AbbVie’s acquisition (via Apogee) deepens its immunology pipeline by adding diverse late-stage assets targeting dermatologic, respiratory, and other inflammatory diseases. The lead candidate, zumilokibart, is a half-life extended monoclonal antibody targeting IL-13 and is described as late-stage in development, supporting continued expansion of AbbVie’s immunology growth platform.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
ABBV0.35
APOG0.30
More News
- Inside Fortescue’s billion-dollar bet to decarbonize mining—and help rebuild Ukraine
- Royal Caribbean to buy 50% stake in Sandals Resorts for $3 bln
- RBC upgrades Lakefront Biotherapeutics stock rating on autoimmune drug potential
- Pollen Street explores strategic options including going private
- This oil giant has lagged its leading rivals through two energy crises. Now one Wall Street giant says it’s time to buy.
- Nvidia's Demand Is Outpacing Its 70% Growth Forecast, and That Is Just the Beginning